Announcements Trials
Browse Landscape

Status

No longer available 2Approved for marketing 1

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioma 2

Interventions

trametinib 4nilotinib 4elotuzumab 4dabrafenib 4Amifampridine 4regorafenib 3pembrolizumab 3midostaurin 3fludarabine phosphate 3fludarabine 3Nivolumab 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Cyclophosphamide 3Crizotinib 3Bortezomib 3Axitinib 3venetoclax 2veliparib 2tazemetostat 2talimogene laherparepvec 2navitoclax 2gallium 68 PSMA-11 2ceritinib 2carbon-11 acetate 2aldesleukin 2Whole-Body Irradiation 2Trabectedin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
No longer available × Expanded_access × TIC10 compound × Clear all
NCT05392374 2022-05-26

Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas

Jazz Pharmaceuticals

No longer available
1 FDA
CNS

Glioma

NCT03134131 2022-03-14

Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

Jazz Pharmaceuticals

No longer available
1 FDA
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡